Rwanda vs Venezuela: Average cost of drugs for extensively drug-resistant tuberculosis
Rwanda
1,483 constant 2022 US$
in 2024
Venezuela
1,234 constant 2022 US$
in 2024
Rwanda rank
35th
Venezuela rank
38th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Rwanda
- Venezuela
How they compare
Rwanda currently reports 1,483 constant 2022 US$ against 1,234 constant 2022 US$ in Venezuela, a difference of 249 constant 2022 US$.
That makes Rwanda's figure about 1.2 times Venezuela's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Rwanda ahead.
Rwanda ranks 35th and Venezuela ranks 38th of 56 countries.
Rwanda has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Rwanda | Venezuela | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,647 constant 2022 US$ | 4,182 constant 2022 US$ | 1,465 constant 2022 US$ | Rwanda |
| 2020s | 3,070 constant 2022 US$ | 1,673 constant 2022 US$ | 1,397 constant 2022 US$ | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Rwanda or Venezuela?
- Rwanda, at 1,483 constant 2022 US$ against 1,234 constant 2022 US$ in Venezuela as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Rwanda and Venezuela?
- 249 constant 2022 US$, with Rwanda ahead.
- How many years of comparable data are there for Rwanda and Venezuela?
- 8 years are reported by both, from 2017 to 2024.
- How do Rwanda and Venezuela rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Rwanda ranks 35th and Venezuela ranks 38th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.